Evidence map›Paper›PMID 42835565›Full record

ArticleERJ open research2026

Ever-smokers in Norway and lung cancer: median time from self-reported smoking debut to lung cancer diagnosis in 11 prospective population studies (CONOR).

Olav Toai Duc Nguyen, Ioannis Fotopoulos, Ioannis Tsamardinos, Vincenzo Lagani, Oluf Dimitri Røe

Abstract read
In one paragraph

Article in ERJ open research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Olav Toai Duc NguyenNorwegian University of Science and Technology, Department of Clinical Research and Molecular Medicine, Trondheim, Norway.
Ioannis FotopoulosUniversity of Crete, Department of Computer Science, Heraklion, Greece.
Ioannis TsamardinosUniversity of Crete, Department of Computer Science, Heraklion, Greece.
Vincenzo LaganiBiomedical Sciences Division, King Abdullah University of Science and Technology, Thuwal, Saudi Arabia.
Oluf Dimitri RøeNorwegian University of Science and Technology, Department of Clinical Research and Molecular Medicine, Trondheim, Norway.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Tobacco smoking patterns and lung cancer incidence are closely related, but with years of lag. Most smokers start smoking as teenagers, and lung cancer is diagnosed at a median age of 70 years. However, the median lag time between smoking consumption and lung cancer incidence and smoking-related mortality is commonly reported to be up to 40 years. Here we investigate the median lag time from smoking debut to lung cancer diagnosis in Norway. Methods: We used the Cohort of Norway (CONOR), consisting of linked data from 11 Norwegian prospective population-based cohorts (n=180 534). The study included 80 761 ever-smokers, where 1336 developed lung cancer. Median follow-up time from inclusion in the CONOR study was 11.9 years (0.0-20.8 years) and follow-up from self-reported smoking debut was 44.2 years (2.7-85.4 years). The time from smoking initiation to lung cancer diagnosis was calculated for all cases. Results: The median age of lung cancer diagnosis is 72.5 years. The mean and median time from smoking debut to lung cancer diagnosis are 51.9 (30.2-69.1) and 53.3 years, respectively. The median time from smoking debut until lung cancer diagnosis is >40 years (p<0.001). There is a shorter median lag time in women compared to men and in current smokers compared to former smokers, 48.6 Conclusion: The latency between smoking debut and lung cancer diagnosis in Norwegian ever-smokers is much longer than what has previously been reported. Women and current smokers have a shorter time to diagnosis than men and former smokers, respectively. This is important knowledge in the planning of future healthcare, lung cancer screening, and prevention measures.

Identifiers

PMID42835565
PMCPMC13636103

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.